Silence Therapeutics PLC Silence Therapeutics appoints Head of R&D and CMO
April 16 2019 - 2:01AM
RNS Non-Regulatory
TIDMSLN
Silence Therapeutics PLC
16 April 2019
Silence Therapeutics appoints Giles Campion as Head of R&D
and Chief Medical Officer
April 16, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, is
pleased to announce the appointment of Giles Campion, MD as Head of
R&D and Chief Medical Officer, effective 1 June 2019.
An expert in translational medicine, Dr. Campion is a highly
experienced biotech and pharmaceutical professional, bringing more
than 20 years of experience in the industry. Most notably he served
as Chief Medical Officer and Senior Vice President of R&D at
Prosensa from 2009 to 2016, a European biotech company advancing
oligonucleotide therapies for rare diseases, notably Duchenne
muscular dystrophy (DMD). During this time the company signed a
collaboration agreement with GSK worth up to $655 million with
double digit royalties. Prosensa went on to list on Nasdaq in 2013,
raising $90 million in an initial public offering nine times
oversubscribed, and was ultimately acquired by Biomarin in 2015 for
$680 million.
Previously, Giles held senior R&D roles at Novartis where he
was a key member of a task force that defined the shape of a new
integrated research organisation. Most recently, he served as Chief
Medical Officer for Albumedix , Advisor to Myotherix, and a
co-founder of PepGen, all companies focusing on therapies for rare
diseases. At Albumedix his remit was to build a development
portfolio based on the company's recombinant albumin platform and
his work was instrumental in product development and an eventual
financial exit for the owners of the company.
Dr. Campion holds a medical degree and doctorate from Bristol
University and is Board certified in rheumatology.
Commenting on the appointment, Dr. David Horn Solomon, Chief
Executive Officer, said:
"On behalf of the Board of Silence Therapeutics, I am delighted
to welcome Giles as the new Head of R&D and Chief Medical
Officer. He has an outstanding track record of leading scientific
development and advancing oligonucleotide-based medicines and is
therefore ideally qualified to accelerate the development of our
current and future pipeline. Giles is a valuable addition to the
management team and his expertise will help the company to deliver
on its core mission of tackling the unmet medical needs of patients
suffering from rare conditions."
Dr. Giles Campion, newly appointed Head of R&D and Chief
Medical Officer of Silence Therapeutics, said:
"Silence Therapeutics is at the forefront of an extremely
promising new class of RNA therapeutics and offers an exciting
approach to tackling the unmet medical needs of patients suffering
from serious diseases. I look forward to working with David and the
management team as the Company looks to advance into the clinic in
2019 with the planned commencement of clinical trials for lead
candidate SLN124 in Iron Overload Disorders including Beta
Thalassemia."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive 6900
Officer
Dr Rob Quinn, Interim Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
Peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAXLSFEFNEFF
(END) Dow Jones Newswires
April 16, 2019 02:01 ET (06:01 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024